Tag: Cancer: Rectal
Triple Treatment Combo Beneficial in BRAF-Mutant CRC
Irinotecan, cetuximab, and vemurafenib improve progression-free survival in BRAFV600E-mutated colorectal cancer
Early-Onset CRC Incidence Examined by Histologic Subtype
Adenocarcinomas increasing in most early-onset subgroups; carcinoid tumors increasing more steeply in all age groups
Recurrence Risk Low After One Year of Watch-and-Wait for Rectal Cancer
Authors say these findings suggest no need for intensive surveillance after three years
Less Invasive Treatment Feasible for Early-Stage Rectal Cancer
High level of organ preservation, improved QoL seen with short-course radiotherapy followed by transanal endoscopic microsurgery
Hot Spots ID’d for Higher CRC Mortality in Younger Women
Nearly one in 16 U.S. counties are hot spots, with the majority in the South
Pembrolizumab Slows MSI-H-dMMR Metastatic CRC
Pembrolizumab superior to chemo for progression-free survival among patients who had not previously received treatment
Laparoscopic Resection May Be An Option for CRC Liver Metastases
For resectable colorectal liver metastases, five-year survival rates similar with laparoscopic, open surgery
‘Watch and Wait’ Feasible for Some Rectal Cancer Patients
Some patients with complete response to neoadjuvant chemoradiation may wish to defer surgery
USPSTF Issues Draft Recommendation for CRC Screening
Benefit substantial for adults aged 50 to 75 years; benefit moderate for adults aged 45 to 49 years
ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer
Neoadjuvant RT recommended for stage II to III rectal cancer; RT should be performed preoperatively
